If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
82
results.
Updated on
15/07/2026 [07:55:00]
Results 25 to 50 of 82
Absstract of: CN118846069A
The invention relates to the field of medicine, in particular to a pharmaceutical composition and a preparation method and application thereof.The pharmaceutical composition comprises a first effective component, a second effective component and a pharmaceutically acceptable carrier or auxiliary material, the microbial agent comprises any one or more of staphylococcus aureus, bordetella pertussis, diphtheria toxoid, tetanus toxoid, typhoid bacillus or paratyphoid bacillus, and the second effective component comprises polyinosinic acid, polycytidylic acid and vitamin. The pharmaceutical composition belongs to artificial active immunotherapy aiming at tumors, can'stimulate 'the whole immune system, enables the therapy of activating the human immune system by bacteria to kill cancer cells to be quite stable and reliable, can remarkably save and prolong the life of cancer patients, has extremely high safety and extremely small toxic and side effects, and is suitable for clinical application. And the preparation cost is low.
Absstract of: US20260139012A1
A method for increasing the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.
Absstract of: US20260140114A1
The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
Absstract of: AU2026203336A1
Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens. ay a y
Absstract of: US20260137765A1
A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
Absstract of: AU2026203393A1
DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being: - devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6’ of the non-reducing end of their lipid A domain by a 10 hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group. It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory 15 diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject. - 10 - ay a y - - 1
Absstract of: US20260137738A1
The present invention relates to a novel bacteriophage OPT-SALO1 with specific killing ability for Salmonella enterica, an antibiotic composition comprising the bacteriophage, a composition for adding to a feed, a feed, a disinfectant or a cleaning agent, and a method for preventing or treating infectious diseases caused by Salmonella enterica comprising a step of administering the bacteriophage to a subject.
Absstract of: WO2026102349A1
Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).
Absstract of: WO2026098490A1
Disclosed in the present application is the use of Salmonella typhimurium-derived glutamate dehydrogenase and related biomaterials thereof in amino acid synthesis. Provided in the present application is the use of Salmonella typhimurium-derived glutamate dehydrogenase for improving the L-amino acid yield of a microorganism. In the present application, an optimized coding gene of the Salmonella typhimurium-derived glutamate dehydrogenase is further obtained by means of codon optimization, and the introduction of the optimized coding gene into a recipient microorganism can significantly improve the L-amino acid yield of the recipient microorganism.
Absstract of: US20260131039A1
This disclosure relates to a method for sanitizing a space. The method includes applying a composition containing triethylene glycol into a space containing a pathogen (e.g., a Staphylococcus, a Pseudomonas, a Listeria, Salmonella, Klebsiella, a mycobacterium, a mold, or a spore) in an amount effective to inactivate the pathogen.
Absstract of: US20260132409A1
The present disclosure provides fusion proteins comprises fusion proteins comprising the signal sequence of PduB or PduM and a heterologous protein, as well as constructs for expressing the fusion proteins, and methods of their use. The fusion proteins are designed to deliver the heterologous proteins to bacterial microcompartments and modify the 1,2-propanediol metabolic pathway.
Absstract of: WO2018208840A1
Provided are novel methods for screening and testing for pathogens in food, water, and bodily fluids using methods that are faster to complete than conventional methods of culturing and plating that require lengthy times in properly equipped labs. The invention utilizes specific, rapid and sensitive optical detection to capture small concentrations of the target bacteria and render them amenable for detection with various specific synthesis binding agents approaches. The technique merges capture and detection steps with quantification unit suitable to provide results in a relatively shorter time current detection methods.
Absstract of: CN121995052A
0001 本发明属于生物检测技术领域，具体公开了一种基于SERS的快速超灵敏检测大肠杆菌O157:H7的方法，包括如下步骤：制备免疫磁珠捕获纳米粒子、制备贵金属或贵金属复合纳米粒子溶胶、制备免疫贵金属或贵金属复合信号纳米粒子、制备三明治式夹心结构、大肠杆菌O157:H7检测。本发明的方法以抗体作为特异性识别元件，同时特异性结合并测定大肠杆菌O157:H7，一方面能够稳定纳米材料在检测体系中的分散状态，另一方面能够高特异性和高亲和力地识别目标蛋白，并且稳定性好，制备成本低，在很大程度上提高了检测的准确性；本发明检测速度更快本发明检测流程极简，用时短，适配现场快检与批量筛查，同时检出限低，兼具超快检测速度与超高检测灵敏度，可精准识别痕量目标菌体。
Absstract of: US20260124255A1
0000 A genetically modified Salmonella cell (GMSC) engineered to display pattern-associated and danger-associated molecular patterns to recruit and enhance innate immunity and exhibit specific targeting to cells and regulated delayed lysis in vivo, the GMSC comprising a first heterologous nucleic acid that encodes a first gene product that causes the GMSC to be selectively localized to and/or internalized by a target cell in vivo and a second heterologous nucleic acid that encodes a second gene product that facilitates killing of the target cells following internalization.
Absstract of: US20260124215A1
The present invention relates to compositions and methods for treating or preventing infections, in particular infections by intracellular parasites such as Cryptosporidium spp. The present invention also relates to compositions and methods for treating or preventing viral or bacterial infections, in particular intestinal infections such as those caused by rotavirus and Salmonella spp. Infections. The methods comprise administration of, and the compositions comprise, a farnesyl-diphosphate farnesyltransferase 1 (FDFT1) inhibitor, such as lapaquistat.
Absstract of: WO2025003119A1
The invention relates to a method for detecting and confirming at least one Shiga toxin-producing Escherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.
Absstract of: WO2025003117A1
The present invention relates to a gelled reaction medium for detecting, identifying, and/or isolating at least one Shiga toxin-producing strain of E. coli, the reaction medium comprising: - at least one toxin inducer, - at least one agglutinating conjugate comprising at least one specific binding partner of STX1 and/or at least one specific binding partner of STX2, coupled to a nanoparticle; - a concentration gradient of a compound for inhibiting non-target bacteria. The present invention also relates to the associated method for detecting and/or isolating Shiga toxin-producing E. coli which is likely to be present in a sample comprising enterobacteria.
Absstract of: WO2025037284A2
A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
Absstract of: CN121974501A
The invention relates to a method for producing a water environment protective agent by fermenting hermetia illucens larva slurry, and belongs to the technical field of microbial fermentation. According to the present invention, the hermetia illucens larvae are adopted as the main raw material, the main raw material is ground into the slurry through the colloid mill, the small amount of the carbon source is supplemented, the Phaffia rhodozyma CGMCC NO.29217, the Bacillus coagulans CGMCC NO.5233 and the Clostridium butyricum CGMCC NO.4729 are subjected to the mixed bacteria synergistic fermentation, and the produced product can be widely used in the aquaculture and other application scenarios. Fermented hermetia illucens larva serous fluid is rich in astaxanthin, a fermented product has obvious acid fragrance and no peculiar smell, the total number of probiotics is larger than or equal to 5.0 * 10 < 8 > cfu/g, the pH value is smaller than 4.50, and the content of small molecule active polypeptide (acid soluble protein) of the fermented product is increased by 2.5-3 times compared with that before fermentation. Bacillus subtilis CGMCC (B) 63501 is used as indicator bacteria to detect that the content of bacteriostatic active substances after fermentation of hermetia illucens larva serous fluid is larger than 1.0 g/kg, pathogenic bacteria such as salmonella, vibrio parahaemolyticus and vibrio cholerae are not detected, and normal-temperature storage can be achieved. The preparat
Absstract of: CN121983118A
The invention discloses a method for analyzing the influence of salmonella infection on chicken liver transcriptome RNA m6A modification, and relates to the technical field of bioengineering, and the method comprises the following steps: animal model establishment and sample collection, RNA extraction, sequencing and data quality control, bioinformatics analysis and differential m6A peaks identification, and data integration and function enrichment analysis. By integrating MeRIP-seq and a transcriptome sequencing technology, a dynamic regulation and control mechanism of RNA m6A modification in the process of infecting the chicken liver with salmonella is disclosed, an m6A modification and gene expression association analysis framework under an infection model is constructed, the analysis depth of an epigenetic regulation and control mechanism of poultry immune response is remarkably improved, and the application prospect is broad. And by establishing a standardized experimental process and a bioinformatics analysis system, accurate identification of differential modification sites and functional association thereof from a transcriptome level is realized, and a new technical path is provided for poultry disease resistance research.
Absstract of: CN121975745A
The invention relates to a bacteriophage, in particular to a cross-host multivalent bacteriophage and preparation and application of a bacteriostatic agent of the bacteriophage, the multivalent bacteriophage is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2026045. The salmonella bacteriophage CCTCC NO: M 2026045 is found for the first time, is a multivalent bacteriophage, can cross-host infect and split multiple important livestock and poultry intestinal pathogens such as salmonella, escherichia coli, shigella, klebsiella pneumoniae and proteus mirabilis, solves the problem of narrow host range of a single bacteriophage, and improves the prevention and control efficiency. By inhibiting the overgrowth of the gram-negative pathogenic bacteria, the intestinal microecological balance can be regulated, so that the aim of effective prevention and control is fulfilled.
Absstract of: CN121971485A
The invention discloses a nano-enzyme for preventing salmonella pullorum infection, the nano-enzyme comprises kaempferol and cerium ions, the kaempferol and the cerium ions form a kaempferol-cerium composite nano-enzyme CeKae NPs through coordination, and the nano-enzyme has superoxide dismutase (SOD)-like activity and catalase (CAT)-like activity. The invention further discloses a preparation method and application of the nano-enzyme for preventing salmonella pullorum infection. The CeKae NPs nano-enzyme provided by the invention comprises kaempferol and cerium ions, has efficient SOD and CAT nano-enzyme activity, and can realize antioxidant self-cascade nano-enzyme reaction, effectively remove active oxygen and improve the pathological environment.
Absstract of: CN121975962A
The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.
Absstract of: CN121975692A
The invention discloses a rabbit source fermentation lactobacillus mucus RLF77 and an application of the rabbit source fermentation lactobacillus mucus RLF77. The strain is separated from intestinal tracts of weaned young rabbits and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M 20252224. The bacterial strain has the excellent characteristics of being used as a probiotic, being resistant to gastrointestinal tract environment and high in intestinal epithelial cell adhesion rate, and being capable of effectively inhibiting various pathogenic bacteria such as escherichia coli, salmonella and the like. Animal experiments show that the production performance of weaned young rabbits can be remarkably improved, the diarrhea rate can be reduced, the survival rate and the oxidation resistance can be improved by feeding the rabbit-derived RLF77 strain, and the effect is superior to that of non-rabbit-derived probiotics. The invention provides a new strain resource for developing green breeding products for replacing antibiotics.
Nº publicación: CN121970804A 05/05/2026
Applicant:
ZHONGKAI UNIV OF AGRICULTURE AND ENGINEERING
\u4EF2\u607A\u519C\u4E1A\u5DE5\u7A0B\u5B66\u9662
Absstract of: CN121970804A
The invention discloses a salmonella bacteriophage nano-emulsion preparation as well as a preparation method and application thereof. The salmonella bacteriophage nano-emulsion preparation is mainly prepared from the following active ingredients in percentage by mass: 5 to 15 percent of salmonella bacteriophage suspension, 84 to 94 percent of edible oil, 0.5 to 3.0 percent of Pickering stabilizer dispersion liquid and 0 to 2.0 percent of protective agent. The invention also discloses a preparation method of the salmonella bacteriophage nano-emulsion preparation and application of the salmonella bacteriophage nano-emulsion preparation in bacteriostasis and preservation of meat products. The salmonella bacteriophage nano-emulsion preparation disclosed by the invention is more essential in stable mechanism, more stable in system, more beneficial to bacteriophage activity maintenance, better in food applicability, safe, friendly, more durable in bacteriostatic action and more suitable for fresh keeping of meat products when being applied.
BOPI
Electronic site
